The transmission of cytomegalovirus (CMV) to transplant recipients via transfused blood is well documented and has been extensively reviewed (1, 6). Although blood transfusions may account for most CMV infection in organ transplants (1), neonates (12), and heart surgery (8), there is no unanimity as to the source of the latent virus; it has been reported to be associated with leukocytes (8, 11), predominantly polymorphonuclear (10), and associated with T cells (4). The concentration of virus in blood from a latently infected blood donor is very low, with virus being recoverable from only 3 out of 106 T cells (4). The extended period of time required for CMV isolation, by whichever method, including modern techniques such as hybridization, render rapid direct demonstration of infection in a donor impracticable at the present time.
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Serology is the only practicable system at present for the selection of blood donors with a high probability of being free of virus. Although there appear to be no data from which to determine the correlation between the transmission of CMV and the antibody titer of donors, it has been shown that there is an association between the presence of antibody in mother's blood and acquisition of CMV during the first year of an infant's life; 24 healthy newborns were assessed (9) . Of 13 infants that did not become infected with CMV, the mothers of 10 had antibody titers of <1:8 by complement fixation (CF), and three mothers had CMV antibody titers of 1:16. Of 11 infants proved to be excretors of CMV at some time during the first year of life, the mothers of 7 had CMV antibody titers of 1:16 to 1:64, and four mothers had titers of -1:8. These results suggest that the higher the antibody titer in the blood of a subject the greater is the probability that the individual can transmit CMV infection. Also, there was a positive association between the level of CMV serum antibody by CF and excretion of virus in the urine (7). More pertinently, Yeager et al. (12) showed that when using a titer of -1:8 by indirect hemagglutination (IHA) as the criterion for seropositivity, infants of seronegative mothers who received blood cells from seronegative donors did not acquire CMV infection. Conversely, infants of CMV seronegative mothers who received red blood cells from seropositive donors had an approximately 20% infection rate when the transfused volume was .50 ml. These results suggest that donors with an antibody level of <1:8 by IHA most likely lack the potential to transmit CMV infection. It is therefore important that health care facilities use a reliable and In all of the commercial tests, the base-line positive titers used were those recommended by the manufacturers. All tests used an antigen or antigens prepared from the AD169 strain of CMV.
Analysis of results. Accuracy, sensitivity, specificity, false-positive rate, and false-negative rate were The screening of donors is a special application of diagnostic serology that identifies individuals whose CMV antibody titer is of such a level that they are very unlikely to transmit CMV to a recipient. Such a test is often required to produce a result within 1 working day when blood donors are urgently required after a bone marrow transplant, so that a turnaround time of .6 h is a necessary characteristic of the test.
This factor rules out direct culture methods since these will not give a presumptive negative result in less than 2 weeks, and the results when looking for evidence of latent CMV infection are unlikely to be reliable (6) . The CF test, using overnight fixation at 4°C, is also eliminated on the basis of a turnaround time of 24 h, as also is an EIA test using overnight binding at 4°C (2) .
The costs of false results are an important consideration. The most costly errors inherent in a test methodology are false-negative results. A test giving a significant proportion of falsenegative results will cause donors to be considered for blood or organ donation who are potential transmitters of CMV infection. In our study, two tests fell into this category, CF (falsenegative rate, 25%) and the standard EIA (falsenegative rate, 13%). We would emphasize, however, that we tested only one commercial EIA kit and used only one reader. Other EIA test kits may vary in this respect. Also, we did not compare these results with overnight EIA (2) results, since that was outside of this study. Of the remaining three tests, IHA was the only one which gave a 0% false-negative rate. Falsepositive results are less costly. In this case, a proportion of negative individuals will be excluded from the donor pool, but no hazard is posed to the recipient. It is preferable, however, to keep the proportion offalse-positive results to a minimum to maximize the number of donors available for cross-matching. In our study, IFA gave an unacceptably high false-positive rate (32%), and SFI gave a false-positive rate of 12%. The IHA test showed only a 1% false-positive rate.
The test of choice then, from our results, is the IHA test. It gave no false-negative results, minimizing the possibility of CMV being transmitted to the recipient, and it gave only a 1% false-positive rate, maximizing the number of available donors; it gave the best ranking in terms of practicality and appeared to give reproducible results. The test does not require special instrumentation, is technically simple to perform, and has a short turnaround time. It has, however, two disadvantages. The test is not easy to read after only 90 min of incubation; the patterns are unclear. It is preferable to read the test after 4 to 18 h; however, in checking several hundred sera in routine work, we have not found any discrepancy between the 2-h and 18-h readings. Also, nonspecific results were obtained with four sera (3%) due to nonspecific agglutination in the erythrocyte controls. Continued routine use has confirmed this level of nonspecific reactors. This means a loss of 3 to 4% of the CMV-negative donors from an available pool, which we consider acceptable.
The experiments reported above were undertaken to select the best commercially available test for the purpose of minimizing the transmission of CMV from latently infected blood donors to recipients. However, the added hazard of the viremic acute or convalescent CMV case has to be considered. In a convalescent case, antibody can be expected to be detectable by 8 to 12 days after onset of clinical disease by CF (determined from a review of 10 cases diagnosed by rising CF titer in our own laboratory), and these cases would be eliminated on the basis of detected antibody. We emphasize, however, that the performance of the IHA test used here has not yet been evaluated on sera from known early seroconversions; however, so far we have not been able to detect CMV IgM antibody in three sera by using the kit in parallel with IFA to test immunoglobulin fractions separated on sucrose density gradients (unpublished data). Cases with clinical signs and symptoms would, hopefully, be eliminated on clinical grounds. This leaves an indeterminate number of subclinical cases in the initial phase of a CMV infection and without detectable CMV antibodies who may pose a serious hazard to a recipient but cannot rapidly and economically be identified at the present time.
There is presently no direct and easy method of demonstrating latent CMV infection in organ donors, and it is known (1) that renal allograft recipients who are seronegative before transplantation and receive a kidney from a donor who is seronegative never shed CMV after transplantation, whereas recipients, whether seropositive or seronegative, who receive a kidney from a seropositive donor usually shed virus after transplant. The IHA test has the potential to be applied as a screening test to organ donors and recipients.
